Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Navicixizumab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colon cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Rectal cancer; Solid tumours; Triple negative breast cancer
  • Focus Therapeutic Use
  • Sponsors Feng Biosciences

Most Recent Events

  • 21 Jan 2023 Trial design and enrollment plan from Colorectal cancer cohort (A1 and A2 cohorts) presented at the 2023 Gastrointestinal Cancers Symposium
  • 10 Dec 2022 Trial design, presented at the 45th Annual San Antonio Breast Cancer Symposium
  • 08 Sep 2022 According to a OncXerna Therapeutics media release, first patient has been dosed in this study. Currently colorectal and triple negative breast cancer cohorts are open for enrollment and ovarian cancer and gastric or gastroesophageal cancer cohorts may be opened in the future.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top